Lifebrain is the leading Group in Italy in laboratory medicine for patients, healthcare facilities and businesses. Founded by Prof. Michael Havel and Dr Bernard Auer in 2013, it is now the largest provider of laboratory clinical analyses in the fields of clinical chemistry, haematology, immunochemistry, microbiology, molecular biology, cytology and pathology. With the acquisition of Laboratorio Giusto [Giusto Laboratory] in 2018, the Lifebrain Group also entered the food and environmental analysis sector, and in 2019 the Lifebrain Group increased its presence to over 360 sites in 17 regions. Thanks to its network of laboratories, professional excellence and latest-generation technologies, the Lifebrain laboratory group now has the highest growth rate in Europe
✓ A network of 320 sites in 17 regions — a far-reaching network throughout Italy
✓ More than 1,567 employees taking care of our customers
✓ A total of more than 25 million tests per year
✓ More than 1,500 analytes tested in four regional hubs and specific laboratories
✓ Expertise in the food and environmental analysis sector thanks to the acquisition of Laboratorio Giusto, one of the largest Italian companies in the sector, with a commanding presence in Northern Italy.
Establishment of the Lifebrain Group, with the objective of creating a network of laboratories in Central Europe, starting in Switzerland.
Entry into the Italian market with the acquisition of the Laboratorio Analasi Guidonia [Guidonia Analysis Laboratory], followed by the first acquisitions in Apulia.
Further acquisitions in Emilia-Romagna, Basilicata, Liguria, Campania, Lombardy and the Marche. Thanks to the growth of its laboratory network, the Lifebrain Group became the leading laboratory group in Lazio.
Sale of the Swiss assets and a strategy of focussing on the Italian market.
Creation of three hubs in the north/centre/south with a total of 145 sites.
The Lifebrain Group became No. 2 in Italy and No. 1 in the Veneto.
Expansion of the Lifebrain Group into four new regions. The network of laboratories extended across 15 regions with 204 sites in Italy.
Lifebrain was acquired by Investindustrial, a group leader in independent investment management, with a capital fund of €6.8 billion.
Acquisition of the Laboratorio Giusto and entry into the environmental and food analysis market. A widespread presence, with 270 laboratories and collection centres in 16 Italian regions, and a turnover exceeding 110 million euros.
The Lifebrain Group continued to increase its presence in Italy with 308 sites in 16 regions and a turnover of 158 million euros.
The Lifebrain Group continued to increase its presence in Italy with 360 sites in 17 regions and a turnover of 160 million euros.
Year 2020: expected turnover and number of sites.
Univ. Prof. Dr Michael Havel
Professor Havel is co-founder and CEO of the Lifebrain Group and has successfully completed more than 120 acquisitions over the last five years.
He previously successfully founded FutureLAB (2004–2009), the result of the merger of two groups of Austrian laboratories, and expanded this with the acquisition of 40 small- and medium-sized laboratories in Austria and six other European countries (the Czech Republic, Slovakia, Hungary, Germany, Switzerland and Romania). With more than 120 sites, FutureLAB became one of the leading private laboratory groups in Europe with a turnover of around 120 million euros. In just four years, the value of FutureLAB’s business grew from around €10 million to an exit value of €270 million.
Prior to FutureLAB, Professor Havel worked in the University of Vienna’s hospital division as a professor of surgery (1992–2001), focussing on cardiac, thoracic and vascular surgery. In this role he published more than 350 academic articles and was a respected speaker at national and international congresses.
Professor Havel has gained extensive experience in business management, primarily with the financing and management of private companies. In 2013 he founded Lifebrain AG with his previous management team and he has served as CEO ever since.
Dr Auer is the co-founder and CFO of the Lifebrain Group and has completed more than 120 acquisitions over the last five years. He was previously the chief financial officer of FutureLAB from the end of 2006 to 2011. He was responsible for financial management, planning & control and due diligence processes, and was in direct contact with investors, bondholders and banks, and he coordinated the sale of the company. He later held the position of CFO of the new Synlab Group.
Prior to joining the Lifebrain management team, Dr Auer served as CFO of an internet-focused holding company from 2011–2013.
Dr Auer began his professional career as Group Controller of Austrian Airlines AG (2001–2005) after which he took over the position of Finance and Control Director in 2005. Dr Auer is also a qualified “Public Accountant” and “Treasury Professional”.
Dr Manca has held the position of General Manager of Lifebrain Group’s operations since January 2019.
He previously held the position of CFO and Director of the Gruppo Ospedaliero San Donato–San Raffaele [San Donato-San Raffaele Hospital Group] (2005–2018), where he was responsible for the Group’s financial management, treasurer’s office and M&A (mergers and acquisitions), as well as for the coordination of management control.
In addition, he held the position of CEO for the subsidiaries GSD Sistemi e Servizi [San Donato Group Systems and Services] and the Istituti Clinici di Pavia e Vigevano [Clinical Institutes of Pavia and Vigevano] and the position of Financial Attorney for the Università Vita-Salute San Raffaele [Vita-Salute San Raffaele University].
Before joining the Gruppo Ospedaliero San Donato–San Raffaele, Dr Manca held the role of Credit Analyst for Mediobanca (2003–2005) with particular attention to analysis and financial rating, thus supporting the financial acquisition team.
Dr Manca is also an adjunct professor at the Università degli Studi di Pavia [University of Pavia].
Dr Giusto holds the position of General Manager of the Lifeanalytics Group.
After graduating in chemical sciences, he acquired substantial experience of chemical and microbiological analyses while working as a laboratory technician and he has written a series of publications in scientific journals in the environmental sector.
Since 2009 he has also held the position of Key-Account Manager and Sales Director of Giusto Laboratories.
He is also responsible for coordinating training courses in the fields of science and safety at work. In 2014 he collaborated with the Università degli Studi di Verona [University of Verona] on the subject of emerging organic contaminants and innovative analytical techniques, with reference to the publication “Human cell-based reporter gene assays for endocrine disrupters, POPs, obesogens and other toxic pathways for drinking water and WTP effluents”.